• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Exor's (ENXTAM:EXO) Ferrari Pact Renewal Just Recast Its Long‑Term Ownership Playbook?

    Simply Wall St·01/08/2026 03:29:31
    Listen to the news
    • Exor N.V. and Piero Ferrari recently renewed their shareholders’ agreement for Ferrari N.V., extending coordinated voting and reciprocal first-offer rights on share transfers through at least January 4, 2029, with a possible automatic three-year extension.
    • This renewal underlines a unified, long-term ownership and governance framework at Ferrari, giving investors clearer visibility on how key shareholders may act on major corporate decisions.
    • We will now examine how this reaffirmed long-term ownership alignment with the Ferrari family shapes Exor’s broader investment narrative.

    Find companies with promising cash flow potential yet trading below their fair value.

    What Is Exor's Investment Narrative?

    To own Exor today, you need to be comfortable with a holding-company story where value is tied to a concentrated portfolio, balance sheet discipline and capital allocation, rather than headline revenue or earnings growth. The renewed shareholders’ agreement with Piero Ferrari fits neatly into that thesis: it appears to firm up Exor’s role as a long-term anchor at Ferrari, reinforcing governance stability rather than creating a new short term catalyst. With Exor still trading well below both analyst fair value estimates and its own reported book value, recent share price weakness and current losses keep the focus on execution: how effectively management recycles capital, manages debt after the €600 million 2035 notes, and narrows the gap between intrinsic value and market price. For now, the Ferrari pact mainly reduces one governance risk, rather than redefining the core ones.

    However, one governance risk may be easing just as other financial pressures build. Exor's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

    Exploring Other Perspectives

    ENXTAM:EXO 1-Year Stock Price Chart
    ENXTAM:EXO 1-Year Stock Price Chart
    Community members on Simply Wall St put Exor’s fair value anywhere from €15.13 to a very large €1,899.30 across 9 views, underscoring how differently people see its sum of the parts. Set that against the current focus on capital allocation discipline and the still-wide discount to book value, and it becomes clear why taking in multiple perspectives really matters here.

    Explore 9 other fair value estimates on Exor - why the stock might be a potential multi-bagger!

    Build Your Own Exor Narrative

    Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    • A great starting point for your Exor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Exor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exor's overall financial health at a glance.

    Searching For A Fresh Perspective?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.